Mathias Gallardo, None;
Marion Munk, Bayer (C), Gensight (C), Isarna Therapeutics (E), Lumithera (C), Novartis (C), Zeiss (C);
Thomas Kurmann, None;
Sandro De Zanet, RetinAI Medical AG (E);
Agata Mosinska, RetinAI Medical AG (E);
Mark van Grinsven, Thirona (E);
Clara Sanchez, None;
Martin Zinkernagel, Allergan (C), Bayer (C), Bayer (F), Boehringer Ingelheim (F), Heidelberg Engineering (R), Novartis (C), Novartis (I), Zeiss (R);
Sebastian Wolf, Allergan (F), Bayer Healthcare Pharmaceuticals (F), Bayer Healthcare Pharmaceuticals (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), Chengdu Kanghong Biotechnology (C), Heidelberg Engineering (F), Heidelberg Engineering (C), Novartis Pharmaceuticals Corporation (F), Novartis Pharmaceuticals Corporation (C), RetinAI Medical AG (C), Roche (F), Roche (C);
Raphael Sznitman, Bayer AG (R), Haag-Streit AG (C), medupdate (R), RetinAI Medical AG (I)